Resistance to the proapoptotic effects of interferon-gamma on melanoma cells used in patient-specific dendritic cell immunotherapy is associated with improved overall survival

Cancer Immunology, Immunotherapy

Volumn 60, Issue 1, 2011, Pages 123-131

  Cornforth, A N ^a   Fowler, A W ^a   Carbonell, D J ^a   Dillman, R O ^a  

^a HOAG MEMORIAL HOSPITAL PRESBYTERIAN   (United States)

Author keywords

Apoptosis; Dendritic cells; Immunotherapy; Interferon gamma; Melanoma

Indexed keywords

CALRETICULIN; DENDRITIC CELL VACCINE; GAMMA INTERFERON; PHOSPHATIDYLSERINE; TUMOR ANTIGEN;

ADULT; APOPTOSIS; ARTICLE; CANCER IMMUNOTHERAPY; CANCER RESISTANCE; CANCER SURVIVAL; CELL STRAIN; CELL STRAIN LU 1205; CLINICAL ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; MALE; MELANOMA CELL; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; UPREGULATION; VACCINE PRODUCTION;

ADULT; AGED; ANTIGENS, NEOPLASM; APOPTOSIS; CALRETICULIN; CELL LINE, TUMOR; DENDRITIC CELLS; DISEASE-FREE SURVIVAL; DRUG RESISTANCE; FEMALE; HUMANS; IMMUNOTHERAPY, ADOPTIVE; INTERFERON-GAMMA; MALE; MELANOMA; MIDDLE AGED; PHOSPHATIDYLSERINES; SKIN NEOPLASMS;

EID: 79953744706     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-010-0925-y     Document Type: Article

References (39)

1. Palucka AK, Ueno H, Fay JW, Banchereau J (2007) Taming cancer by inducing immunity via dendritic cells. Immunol Rev 220:129-150 (Pubitemid 350045575)
2. Tuyaerts S, Aerts JL, Corthals J, Neyns B, Heirman C, Breckpot K et al (2007) Current approaches in dendritic cell generation and future implications for cancer immunotherapy. Cancer Immunol Immunother 56:1513-1537 (Pubitemid 47094397)
3. Cranmer LD, Trevor KT, Hersh EM (2004) Clinical applications of dendritic cell vaccination in the treatment of cancer. Cancer Immunol Immunother 53:275-306 (Pubitemid 38392306)
4. Dillman RO, Selvan SR, Schiltz PM (2006) Patient-specific dendritic-cell vaccines for metastatic melanoma. N Engl J Med 355:1179-1181 (Pubitemid 44394941)
5. Dillman RO, Nayak SK, Barth NM, DeLeon C, Schwartzberg LS, Spitler LE et al (1998) Clinical experience with autologous tumor cell lines for patient-specific vaccine therapy in metastatic melanoma. Cancer Biother Radiopharm 13:165-176 (Pubitemid 28359719)
6. Meyskens FL Jr, Kopecky KJ, Taylor CW, Noyes RD, Tuthill RJ, Hersh EM et al (1995) Randomized trial of adjuvant human interferon gamma versus observation in high-risk cutaneous melanoma: a Southwest Oncology Group Study. J Natl Cancer Inst 87:1710-1713
7. Lotem M, Machlenkin A, Hamburger T, Nissan A, Kadouri L, Frankenburg S et al (2009) Autologous melanoma vaccine induces antitumor and self-reactive immune responses that affect patient survival and depend on MHC class II expression on vaccine cells. Clin Cancer Res 15:4968-4977
8. Fujisawa Y, Nabekura T, Nakao T, Nakamura Y, Takahashi T, Kawachi Y et al (2009) The induction of tumor-specific CD4+ T cells via major histocompatibility complex class II is required to gain optimal anti-tumor immunity against B16 melanoma cell line in tumor immunotherapy using dendritic cells. Exp Dermatol 18:396-403
9. Zoller M, Strubel A, Hammerling G, Andrighetto G, Raz A, Ben-Ze'ev A (1988) Interferon-gamma treatment of B16 melanoma cells: opposing effects for non-adaptive and adaptive immune defense and its reflection by metastatic spread. Int J Cancer 41:256-266
10. Ugurel S, Seiter S, Rappl G, Stark A, Tilgen W, Reinhold U (1999) Heterogenous susceptibility to CD95-induced apoptosis in melanoma cells correlates with bcl-2 and bcl-x expression and is sensitive to modulation by interferon-gamma. Int J Cancer 82:727-736 (Pubitemid 29356973)
11. Ullrich E, Bonmort M, Mignot G, Kroemer G, Zitvogel L (2008) Tumor stress, cell death and the ensuing immune response. Cell Death Differ 15:21-28 (Pubitemid 350286169)
12. Sporri R, Reis e Sousa C (2005) Inflammatory mediators are insufficient for full dendritic cell activation and promote expansion of CD4+ T cell populations lacking helper function. Nat Immunol 6:163-170
13. Obeid M, Panaretakis T, Joza N, Tufi R, Tesniere A, van Endert P et al (2007) Calreticulin exposure is required for the immunogenicity of gamma-irradiation and UVC light-induced apoptosis. Cell Death Differ 14:1848-1850 (Pubitemid 47423653)
14. Fry TJ, Shand JL, Milliron M, Tasian SK, Mackall CL (2009) Antigen loading of DCs with irradiated apoptotic tumor cells induces improved anti-tumor immunity compared to other approaches. Cancer Immunol Immunother 58:1257-1264
15. Obeid M, Tesniere A, Ghiringhelli F, Fimia GM, Apetoh L, Perfettini JL et al (2007) Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat Med 13:54-61 (Pubitemid 46067386)
16. Del Cid N, Jeffery E, Rizvi SM, Stamper E, Peters LR, Brown WC et al (2010) Modes of calreticulin recruitment to the major histocompatibility complex class I assembly pathway. J Biol Chem 285:4520-4535
17. Su Q, Wang S, Baltzis D, Qu LK, Raven JF, Li S et al (2007) Interferons induce tyrosine phosphorylation of the eIF2alpha kinase PKR through activation of Jak1 and Tyk2. EMBO Rep 8:265-270 (Pubitemid 46344592)
18. Dillman RO, Selvan SR, Schiltz PM, McClay EF, Barth NM, DePriest C et al (2009) Phase II trial of dendritic cells loaded with antigens from self-renewing, proliferating autologous tumor cells as patient-specific antitumor vaccines in patients with metastatic melanoma: final report. Cancer Biother Radiopharm 24:311-319
19. Choi D, Perrin M, Hoffmann S, Chang AE, Ratanatharathorn V, Uberti J et al (1998) Dendritic cell-based vaccines in the setting of peripheral blood stem cell transplantation: CD34+ cell-depleted mobilized peripheral blood can serve as a source of potent dendritic cells. Clin Cancer Res 4:2709-2716 (Pubitemid 28523496)
20. Luft T, Pang KC, Thomas E, Bradley CJ, Savoia H, Trapani J et al (1998) A serum-free culture model for studying the differentiation of human dendritic cells from adult CD34+ progenitor cells. Exp Hematol 26:489-500 (Pubitemid 28247315)
21. Dillman RO, Nayak SK, Beutel L (1993) Establishing in vitro cultures of autologous tumor cells for use in active specific immunotherapy. J Immunother Emphasis Tumor Immunol 14:65-69 (Pubitemid 23239942)
22. Dillman RO, Beutel LD, Cornforth AN, Nayak SK (2000) Short-term tumor cell lines from renal cell carcinoma for use as autologous tumor cell vaccines in the treatment of kidney cancer. Cancer Biother Radiopharm 15:161-168 (Pubitemid 30305967)
23. Selvan SR, Dillman RO, Fowler AW, Carbonell DJ, Ravindranath MH (2007) Monitoring response to treatment in melanoma patients: potential of a serum glycomic marker. Int J Cancer 122(6):1374-1383
24. Selvan SR, Carbonell DJ, Fowler AW, Beatty AR, Ravindranath MH, Dillman RO (2010) Establishment of stable cell lines for personalized melanoma cell vaccine. Melanoma Res 20(4)280-292
25. Fojtova M, Boudny V, Kovarik A, Lauerova L, Adamkova L, Souckova K et al (2007) Development of IFN-gamma resistance is associated with attenuation of SOCS genes induction and constitutive expression of SOCS 3 in melanoma cells. Br J Cancer 97:231-237 (Pubitemid 47057470)
26. Panaretakis T, Kepp O, Brockmeier U, Tesniere A, Bjorklund AC, Chapman DC et al (2009) Mechanisms of pre-apoptotic calreticulin exposure in immunogenic cell death. EMBO J 28:578-590
27. Adema GJ, de Vries IJ, Punt CJ, Figdor CG (2005) Migration of dendritic cell based cancer vaccines: in vivo veritas? Curr Opin Immunol 17:170-174
28. Kepp O, Tesniere A, Schlemmer F, Michaud M, Senovilla L, Zitvogel L et al (2009) Immunogenic cell death modalities and their impact on cancer treatment. Apoptosis 14:364-375
29. Martins I, Tesniere A, Kepp O, Michaud M, Schlemmer F, Senovilla L et al (2009) Chemotherapy induces ATP release from tumor cells. Cell Cycle 8:3723-3728
30. Apetoh L, Ghiringhelli F, Tesniere A, Criollo A, Ortiz C, Lidereau R et al (2007) The interaction between HMGB1 and TLR4 dictates the outcome of anticancer chemotherapy and radiotherapy. Immunol Rev 220:47-59 (Pubitemid 350045573)
31. Blank C, Gajewski TF, Mackensen A (2005) Interaction of PD-L1 on tumor cells with PD-1 on tumor-specific T cells as a mechanism of immune evasion: implications for tumor immunotherapy. Cancer Immunol Immunother 54:307-314 (Pubitemid 40238924)
32. Dong H, Strome SE, Salomao DR, Tamura H, Hirano F, Flies DB et al (2002) Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med 8:793-800
33. Hemmi H, Akira S (2005) TLR signalling and the function of dendritic cells. Chem Immunol Allergy 86:120-135 (Pubitemid 40905001)
34. Marin-Gallen S, Clemente-Casares X, Planas R, Pujol-Autonell I, Carrascal J, Carrillo J et al (2010) Dendritic cells pulsed with antigen-specific apoptotic bodies prevent experimental type 1 diabetes. Clin Exp Immunol 160:207-214
35. Ferguson TA, Kazama H (2005) Signals from dying cells: tolerance induction by the dendritic cell. Immunol Res 32:99-108 (Pubitemid 41153617)
36. Kamei T, Inui M, Nakamura S, Okumura K, Goto A, Tagawa T (2003) Interferon-gamma and anti-Fas antibody-induced apoptosis in human melanoma cell lines and its relationship to bcl-2 cleavage and bak expression. Melanoma Res 13:153-159 (Pubitemid 36583977)
37. Tesniere A, Panaretakis T, Kepp O, Apetoh L, Ghiringhelli F, Zitvogel L et al (2008) Molecular characteristics of immunogenic cancer cell death. Cell Death Differ 15:3-12 (Pubitemid 350286167)
38. Perez CA, Fu A, Onishko H, Hallahan DE, Geng L (2009) Radiation induces an antitumour immune response to mouse melanoma. Int J Radiat Biol 85:1126-1136
39. Dillman RO, DePriest C, DeLeon C, Barth NM, Schwartzberg LS, Beutel LD et al (2007) Patient-specific vaccines derived from autologous tumor cell lines as active specific immunotherapy: results of exploratory phase I/II trials in patients with metastatic melanoma. Cancer Biother Radiopharm 22:309-321 (Pubitemid 47067889)